Navigation Links
Surveyed Endocrinologists Consider Eli Lilly's Dulaglutide To Have an Edge Over Competitors for the Treatment of Type 2 Diabetes Patients Who Are Inadequately Controlled On Metformin

BURLINGTON, Mass., Nov. 26, 2013 /PRNewswire/ -- Decision Resources, one of the world's leading research and advisory firms for pharmaceutical and healthcare issues, finds that, among a range of current and emerging therapies, surveyed endocrinologists in the United States and Europe indicate that Eli Lilly's novel glucagon-like peptide 1 (GLP-1) receptor agonist dulaglutide has the optimal balance of efficacy, safety and tolerability, and delivery attributes for the treatment of patients with type 2 diabetes who are inadequately controlled with metformin. In the crowded type 2 diabetes second-line treatment landscape, dulaglutide's delivery attributes give it a slight edge over other currently available and emerging therapies, which include agents from the following drug classes: GLP-1 receptor agonists, dipeptidyl peptidase-IV inhibitors and sodium glucose cotransporter 2 inhibitors.

(Logo: )

The 2013 DecisionBase report entitled Type 2 Diabetes: When Metformin Has Lost the Battle for Glycemic Control, What Antidiabetic Agents Win Endocrinologists' Backing? also finds that surveyed endocrinologists are most compelled by drugs that reduce glycated hemoglobin A1c (HbA1c) levels. However, the high price of novel type 2 diabetes agents could offset endocrinologists' receptivity to such agents. Payers also indicate that they would only accommodate high price premiums in the presence of substantial improvements in efficacy. In addition, U.S. and European endocrinologists regard reductions in bodyweight as an important unmet need, reflecting the high prevalence of excess weight in the type 2 diabetes population.

The findings also reveal that surveyed endocrinologists consider many of the current and emerging type 2 diabetes therapies to provide improvements over the current patient-share leader, Merck's Januvia, despite this agent's reputation as having a good risk-benefit profile. However, the emerging type 2 diabetes therapies, in general, do not provide distinct advantages over the currently available agents.

"With the wider range of treatments available and the benefits of individualizing therapy increasingly being recognized, the decisions facing prescribers and payers regarding second-line antidiabetic agents are more challenging than ever," said Decision Resources Analyst Tim Blackstock, M.B., Ch.B. "As yet, no agent has met the medical needs that have been identified, and significant opportunity remains in the type 2 diabetes market."

About Decision Resources

Decision Resources ( is a world leader in market research publications, advisory services and consulting designed to help clients shape strategy, allocate resources and master their chosen markets. Decision Resources is a Decision Resources Group company.

About Decision Resources Group

Decision Resources Group is a cohesive portfolio of companies that offers best-in-class, high-value information and insights on important sectors of the healthcare industry. Clients rely on this analysis and data to make informed decisions. Please visit Decision Resources Group at

All company, brand, or product names contained in this document may be trademarks or registered trademarks of their respective holders.

SOURCE Decision Resources
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. Two-Thirds of Surveyed U.S. Neurologists Have Prescribed Genzymes Aubagio to Their Multiple Sclerosis Patients at One Year Post-Launch
2. Surveyed EU5 Rheumatologists Prescribe Biologics to Approximately Half of Their DMARD-Treated Psoriatic Arthritis Patients
3. Surveyed EU5 Oncologists Plan Increased Uptake of Perjeta for HER2-Positive Breast Cancer, But Expect Reimbursement Hurdles for Perjeta Plus Kadcycla
4. Surveyed Physicians Report that Invokana Captures a Small Percentage of Patient Share in the Type 2 Diabetes Drug Market, With Significant Increases Expected Six Months from Now
5. Surveyed U.S. Rheumatologists are Moderately Satisfied with Biologic Agents and Xeljanz to Treat Rheumatoid Arthritis
6. More than a Third of Chronic Kidney Disease-Non-Dialysis Patients are Likely Candidates for FG-4592/ASP1517, According to Surveyed EU5 Nephrologists
7. At One Month Post-Launch, Nearly a Quarter of Surveyed U.S. Oncologists Have Prescribed Tafinlar for Malignant Melanoma, Compared to 15 Percent Who Used Mekinist
8. Should Mircera Reach the U.S. Market, Surveyed Nephrologists State that at Least 40 Percent of CKD-ND and Dialysis Patients are Likely Candidates
9. According to Surveyed U.S. Oncologists, Zytiga is the Patient-Share Leader in First-Line Metastatic Castrate-Resistant Prostate Cancer
10. Surveyed U.S. Neurologists Report Greater Overall Satisfaction with Tecfidera than with Platform Injectables and Other Oral Multiple Sclerosis Therapies
11. At One Month Post-Launch, Nearly One-Quarter of Surveyed U.S. Medical Oncologists Have Prescribed Xofigo to Their Prostate Cancer Patients
Post Your Comments:
(Date:11/25/2015)... Nov. 25, 2015  Linden Care, LLC, a retail ... outcomes for patients suffering from chronic pain, said today ... Temporary Restraining Order (TRO) enjoining Express Scripts from unilaterally ... --> --> The ... its legal options. --> ...
(Date:11/25/2015)... , Nov. 25, 2015 On Tuesday, ... federal bellwether trial against Wright Medical Technology, Inc. ... their Conserve metal-on-metal hip implant device, awarded $11 ... a two week trial and three days of ... hip device was defectively designed and unreasonably dangerous, ...
(Date:11/25/2015)... -- Henry Schein, Inc., the world,s largest provider of health ... animal health practitioners, will unveil at the Greater New ... Pavilion , which brings together for the first time ... help any practice or laboratory enter the digital age. ... of experts appearing at the Pavilion. --> ...
Breaking Medicine Technology:
(Date:11/27/2015)... ... November 27, 2015 , ... Intellitec Solutions announced ... User Group (MSDSLUG). Recognized as Microsoft’s official group for end users of Dynamics ... software users, partners, industry experts and representatives. Intellitec Solutions’ membership status demonstrates their ...
(Date:11/27/2015)... Minn. (PRWEB) , ... November 27, 2015 , ... ... start failing. Secura Consultants has prided itself for not only fulfilling the needs ... income protection solutions at an affordable price and providing top-tier customer service. However, ...
(Date:11/27/2015)... , ... November 27, 2015 , ... CBD College ... of Allied Health Education Programs (CAAHEP) awarded accreditation to its Diagnostic Medical Sonography program. ... accredited colleges, as only one of twelve colleges and universities in the state of ...
(Date:11/27/2015)... ... ... Dr. Thomas Dunlap and Dr. Patrick Coleman , cardiologist ... Medicine at St., Joseph Health System’s Santa Rosa Memorial Hospital , co-hosted the ... ways and require time-critical intervention to avoid large area heart damage and progressive infections ...
(Date:11/27/2015)... ... November 27, 2015 , ... Indosoft Inc., ... the incorporation of Asterisk 11 LTS (Long Term Support) into its Q-Suite 5.10 ... brings Q-Suite 5.10 up-to-date with a version of Asterisk that will receive not ...
Breaking Medicine News(10 mins):